pubmed.ncbi.nlm.nih.gov

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma - PubMed

  • ️Sat Jan 01 2011

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

Meng Li et al. Nat Genet. 2011.

Abstract

Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.

PubMed Disclaimer

Figures

Figure
Figure

Comment in

Similar articles

Cited by

References

    1. El-Serag HB, Rudolph KL. Gastroenterology. 2007;132:2557–2576. - PubMed
    1. American Cancer Society. Cancer Facts and Figures 2009. 2009 < http://www.cancer.org/Research/CancerFactsFigures/cancer-facts-figures-2009>.
    1. Farazi PA, DePinho RA. Nat. Rev. Cancer. 2006;6:674–687. - PubMed
    1. Vogelstein B, Kinzler KW. Nat. Med. 2004;10:789–799. - PubMed
    1. Yan Z, et al. Genes Dev. 2005;19:1662–1667. - PMC - PubMed

Publication types

MeSH terms

Substances

Grants and funding